Table 3 Overall survival and lung cancer-specific survival in patients with stage IA non–small-cell lung cancer ≤1 cm and > 1 to 2 cm groups

Wedge vs. seg

1.52 (1.13–2.04)

0.016

1.40 (0.93–2.11)

0.150

1.52 (1.13–2.04)

0.016

1.51 (1.27–1.80)

< 0.001

Wedge vs. lob without LND

1.25 (1.03–1.52)

0.025

1.24 (0.95–1.63)

0.121

1.63 (1.49–1.78)

< 0.001

1.64 (1.44–1.87)

< 0.001

Wedge vs. lob with LND

1.76 (1.49–2.07)

< 0.001

1.75 (1.40–2.21)

< 0.001

1.90 (1.74–2.06)

< 0.001

1.89 (1.69–2.12)

< 0.001

Wedge vs. lob

1.59 (1.36–1.86)

< 0.001

1.58 (1.27–1.96)

< 0.001

1.82 (1.68–1.97)

< 0.001

1.82 (1.63–2.03)

< 0.001

Seg vs. lob without LND

0.82 (0.58–1.16)

0.287

0.84 (0.53–1.36)

0.513

1.16 (1.00–1.36)

0.041

1.08 (0.88–1.33)

0.460

Seg vs. lob with LND

1.15 (0.79–1.67)

0.414

1.24 (0.75–2.07)

0.360

1.35 (1.15–1.57)

< 0.001

1.26 (1.02–1.56)

0.018

Seg vs. lobe

1.05(0.74–1.48)

0.798

1.11(0.69–1.80)

0.642

1.29 (1.11–1.50)

< 0.001

1.20(0.98–1.48)

0.005

Lob without LND vs. with LND

1.40 (1.12–1.74)

0.001

1.41 (1.04–1.91)

0.018

1.15 (1.06–1.24)

< 0.001

1.15 (1.02–1.29)

0.012